JonesResearch initiated coverage of Spyre Therapeutics (SYRE) with a Hold rating and no price target Spyre is a clinical-stage biotech developing half-life extended antibodies for the treatment of inflammatory bowel disease, the analyst tells investors in a research note. The firm sees a balanced risk/reward profile into near-term data catalysts. Spyre ‘s lead monotherapies could drive blockbuster sales, but the opportunities appear priced into the stock, contends JonesResearch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics announces first participants dosed in Phase 1 trial
- Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50
- Spyre Therapeutics Faces Internal Control Challenges
- Spyre Therapeutics announces $200M common stock offering
- Spyre Therapeutics price target raised to $65 from $50 at Baird
Questions or Comments about the article? Write to editor@tipranks.com